TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8723576
Drug: Epoetin alfa
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epoetin alfa 300 IU/kg intravenous (i.v.) twice weekly for 3 weeks
Study: 8723576
Drug: Epoetin alfa
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epoetin alfa 100 IU/kg subcutaneous (s.c.) twice weekly for 3 weeks (with a single i.v. bolus of 200 IU/kg at the first s.c. dose)
Study: 8723576
Drug: Both treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatment groups (i.v. and s.c. epoetin alfa)
Study: 6362676
Drug: Kelfiprim (trimethoprim
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kelfiprim (trimethoprim 250 mg + sulfalene 200 mg)
Study: 6362676
Drug: Co-trimoxazole (trimethoprim
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-trimoxazole (trimethoprim 320 mg + sulfamethoxazole 1600 mg)
Study: 29210520
Drug: MMN (18
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMN (18 vitamins and minerals including 250 μg iodine per day)
Study: 29210520
Drug: LNS (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: LNS (20 g/day of small-quantity lipid-based nutrient supplements with 250 μg iodine)
Study: 29210520
Drug: IFA (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFA (60 mg iron and 400 μg folic acid per day)
Study: 18186579
Drug: Crude rhubarb
Normalized name: RHUBARB
DrugBank: Rhubarb (DB10651)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crude rhubarb treatment (3 g, tid, p.o)
Study: 18186579
Drug: Crude rhubarb
Normalized name: RHUBARB
DrugBank: Rhubarb (DB10651)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crude rhubarb treatment
Study: 15073700
Drug: Aminocaproic acid
Normalized name: Aminocaproic Acid
DrugBank: Aminocaproic acid (DB00513)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aminocaproic acid (100 mg/kg after anesthetic induction, 100 mg/kg on CPB, and 100 mg/kg after protamine)
Study: 15073700
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (10 mg/kg after anesthetic induction, 10 mg/kg on CPB, and 10 mg/kg after protamine)
Study: 11752035
Drug: Angiotensin-converting enzyme
Normalized name: ACE - Angiotensin-converting enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin-converting enzyme inhibition (ACEi) with enalapril 5 mg once daily
Study: 9721002
Drug: Creatine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine supplementation (20 g x day(‐1), given in 4 x 6‐g doses of 5 g creatine monohydrate and 1 g glucose for 5 days)
Study: 2506966
Drug: Topical steroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical steroids and mydriatics (Control)
Study: 28258434
Drug: USG-guided corticosteroid
Normalized name: abiraterone and corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: USG-guided corticosteroid injection (40 mg/2 mL methylprednisolone acetate)
Study: 28258434
Drug: Blinded corticosteroid
Normalized name: abiraterone and corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blinded corticosteroid injection (40 mg/2 mL methylprednisolone acetate)
Study: 21544005
Drug: Intravenous ribavirin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous ribavirin (RBV) at a moderate dose (8.33 mg/kg/dose q 8 hours on day 1, 5 mg/kg/dose q 8 hours on days 2-10)
Study: 21544005
Drug: Intravenous ribavirin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous ribavirin (RBV) at an escalated dose (33 mg/kg on day 1, then 16 mg/kg/dose q 6 hours for 4 days, and 8 mg/kg/dose q 8 hours for 3 days)
Study: 18297416
Drug: Fluoxetine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine plus gabapentin
Study: 31944487
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose tDCS (2.5 mA for 30 min)
Study: 31944487
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose tDCS (0.034 mA for 30 min)
Study: 30139638
Drug: IBI-10090 (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: IBI-10090 (5 μL injection of 517 μg)
Study: 30139638
Drug: Prednisolone acetate
Normalized name: Prednisolone Acetate
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone acetate 1.0% (1 drop 4 times daily for 3 weeks)
Study: 25721132
Drug: Sensor-based interactive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sensor-based interactive exercise training (twice a week for 4 weeks)
Study: 23553157
Drug: Low-sodium diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-sodium diet (1.3 g/d)
Study: 23553157
Drug: High-sodium diet
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-sodium diet (3.8 g/d)
Study: 8991493
Drug: 2 x
Normalized name: anti-HER2 x HER2 ADC
DrugBank: Zanidatamab zovodotin (DB15472)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 x 25 mg clomipramine hydrochloride tablets (Noristan Ltd.)
Study: 8991493
Drug: Anafranil 2
Normalized name: Anafranil 25mg Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anafranil 2 x 25 mg tablets (clomipramine HCl; Ciba‐Geigy (Pty) Ltd.)
Study: 8991493
Drug: 5 x
Normalized name: PAD,ABDOMINAL 5 X 9 STERILE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 x 10 mg clomipramine hydrochloride tablets (Noristan Ltd.)
Study: 8991493
Drug: Anafranil 5
Normalized name: Anafranil 50mg Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anafranil 5 x 10 mg tablets (clomipramine HCl; Ciba‐Geigy (Pty) Ltd.)
Study: 1389190
Drug: Thiopental with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopental with infusion of sufentanil 0.1 microgram/kg/hr
Study: 1389190
Drug: Thiopental with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopental with infusion of fentanyl 1 microgram/kg/hr
Study: 1389190
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of 0.25% to 2% isoflurane
Study: 3999630
Drug: Antihypertensive drugs
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive drugs (including diuretics)
Study: 30473540
Drug: Liraglutide injection:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide injection: 0.6‐1.2 mg/day, 12 weeks, n=52
Study: 30473540
Drug: Metformin (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (oral metformin: 1000‐1500 mg/day, 12 weeks, n=75)
Study: 12393986
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy with or without radiotherapy (26 epirubicin, 19 epirubicin + ifosfamide)
Study: 15658903
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy with or without radiotherapy
Study: 10654875
Drug: 5.0 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5.0 mg/day bisoprolol
Study: 10654875
Drug: 2.5 mg/day
Normalized name: Androderm 2.5 MG/Day 24 HR Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg/day bisoprolol
Study: 10654875
Drug: Healthy control
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Healthy control subjects receiving 5.0 mg/day bisoprolol
Study: 30472215
Drug: CST-AET (Coping
Approvals — FDA: no, EMA: no, PMDA: no
Description: CST-AET (Coping Skills Training for Adherence to Endocrine Therapy)
Study: 27787700
Drug: Desmopressin (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desmopressin (0.4 mg) and Indomethacin (50 mg)
Study: 25919012
Drug: Men with
Normalized name: Peptamen with Prebio Vanilla
Approvals — FDA: no, EMA: no, PMDA: no
Description: Men with HIV plasma VL > 50,000 copies/ml
Study: 21250973
Drug: Revaccination with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Revaccination with non-live vaccines after chemotherapy, starting as early as 3 months post-chemotherapy.
Study: 19283649
Drug: Physical exercise;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical exercise; details on dosage and duration not available
Study: 10965639
Drug: Psychotherapy treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychotherapy treatment for BED
Study: 1291593
Drug: Vaginal micronized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal micronized progesterone (4 g of vaginal cream containing 2.5% natural progesterone)
Study: 27741123
Drug: Robot-assisted gait
Approvals — FDA: no, EMA: no, PMDA: no
Description: Robot-assisted gait therapy (RAGT) combined with rehabilitation therapy (RT)
Study: 27741123
Drug: Rehabilitation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rehabilitation therapy (RT) alone
Study: 18514630
Drug: Amino acid
Normalized name: Amino Acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amino acid (AA) treatment, 70.6 kcal/day (8 g of essential AAs) given at 10:00 am and 5:00 pm
Study: 18514630
Drug: Amino acid
Normalized name: Amino Acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amino acid (AA) treatment
Study: 12417888
Drug: Chlorpheniramine 8
Normalized name: CODEINE 54.3/CHLORPHENIRAMINE 8MG SA TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorpheniramine 8 mg
Study: 1790403
Drug: Sodium fluoride
Normalized name: Sodium Fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium fluoride (NaF) 75 mg/day
Study: 30431567
Drug: Shaft method
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shaft method to place biological mesh
Study: 27208320
Drug: GLIPULIN (exenatide
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLIPULIN (exenatide dosing before meals)
Study: 27208320
Drug: BBI (rapid-acting
Approvals — FDA: no, EMA: no, PMDA: no
Description: BBI (rapid-acting insulin analogs)
Study: 20464583
Drug: Zolmitriptan (Z)
Normalized name: Zolmitriptan
DrugBank: Zolmitriptan (DB00315)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zolmitriptan (Z) 2.5 mg
Study: 16003228
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil (MMF) 1.5 g administered twice daily with CNI dose reduction or discontinuation (group 1: discontinuation, group 2: 50% reduction)
Study: 16003228
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (CNI dose reduction or discontinuation without MMF)
Study: 12534449
Drug: Fluvastatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin (40 mg day-1)
Study: 8542860
Drug: Injection speed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Injection speed of 10 seconds
Study: 8542860
Drug: Injection speed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Injection speed of 20 seconds
Study: 8542860
Drug: Injection speed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Injection speed of 30 seconds
Study: 8542860
Drug: Injection speed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Injection speed of 1 minute (added group)
Study: 21371282
Drug: Antiplatelet therapy:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiplatelet therapy: 325 mg aspirin daily plus 75 mg clopidogrel daily
Study: 21371282
Drug: Antiplatelet therapy:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiplatelet therapy: 325 mg aspirin daily plus placebo
Study: 19621985
Drug: Cyclosporin A
Normalized name: Cyclosporin A
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporin A (CsA) 5 mg/kg infused over 24 h
Study: 15124801
Drug: Methylprednisolone (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone (6 mg/kg BW, administered intravenously in six equal doses at 8 h intervals)
Study: 11786156
Drug: WMS ≤16%
Approvals — FDA: no, EMA: no, PMDA: no
Description: WMS ≤16% with ICD treatment
Study: 8271851
Drug: Thrombolysis followed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Thrombolysis followed by conservative therapy
Study: 2574053
Drug: Phenytoin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenytoin (100 mg intravenously)
Study: 28284776
Drug: 20 and
Normalized name: zinc pyrithione 20 MG/ML [Free and Clear]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 and 35 mg/kg GHB
Study: 28284776
Drug: 35 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 35 mg/kg GHB
Study: 23489776
Drug: Selenium 200
Normalized name: SELENIUM 200MCG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenium 200 μg/day
Study: 23489776
Drug: Selenium 400
Normalized name: selenium 400 MCG in 10 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenium 400 μg/day
Study: 21733952
Drug: Cilostazol (low-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilostazol (low-dose 100 mg/d)
Study: 21733952
Drug: Cilostazol (high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilostazol (high-dose 200 mg/d)
Study: 16988754
Drug: Losartan 100
Normalized name: LOSARTAN 100MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 100 mg + Amlodipine 5 mg
Study: 11192339
Drug: Preventive occupational
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preventive occupational therapy (OT) for 9 months
Study: 9720932
Drug: Intra-arterial infusion
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial infusion of doxorubicin
Study: 7999406
Drug: naproxen 1500
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: naproxen 1500 mg
Study: 7999406
Drug: slow-release morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: slow-release morphine 60 mg
Study: 3213896
Drug: Buflomedil 600
Normalized name: buflomedil 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buflomedil 600 mg.d-1 in association with anti-edema drugs
Study: 3213896
Drug: Anti-edema drugs
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-edema drugs only
Study: 28666299
Drug: Trimethoprim 80
Normalized name: trimethoprim 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim 80 mg and Sulfamethoxazole 400 mg
Study: 28666299
Drug: Nitrofurantoin 100
Normalized name: nitrofurantoin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrofurantoin 100 mg
Study: 24262593
Drug: Fenoverine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenoverine (100 mg three times a day)
Study: 24262593
Drug: Trimebutine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimebutine (150 mg three times a day)
Study: 16548939
Drug: Maximal tailored
Normalized name: Spirulina maxima preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maximal tailored behavioral treatment (baseline tailored brief motivational intervention, quit date behavioral skills counseling session, relapse prevention follow‐up session)
Study: 16548939
Drug: Minimal treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimal treatment (brief advice using the National Cancer Institute's 4 As model)
Study: 8728305
Drug: Nifedipine SR
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine SR 20 mg twice daily
Study: 92897
Drug: No injections
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No injections (Control group)
Study: 92897
Drug: Immunotherapy (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy (both treatment groups)
Study: 31775650
Drug: Care coordination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Care coordination intervention involving practical nurses trained to assess medication risks and coordinating with pharmacists and physicians.
Study: 25098557
Drug: Normal Protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal Protein (NP) breakfast (350 kcal, 13 g protein)
Study: 25098557
Drug: High Protein
Normalized name: Vital High Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: High Protein (HP) breakfast (350 kcal, 35 g protein)
Study: 17466735
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of botulinum toxin type A (Botox) (200 or 300 U)
Study: 15983826
Drug: Aprepitant (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprepitant (125 mg on day 1, 80 mg on days 2 and 3)
Study: 11997270
Drug: Oral conjugated
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral conjugated equine estrogen (0.625 mg/d)
Study: 11997270
Drug: Estrogen plus
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen plus progestin (medroxyprogesterone acetate 2.5 mg/d)
Study: 9806688
Drug: 0.75% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75% bupivacaine (1.5 mL)
Study: 9806688
Drug: 1% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% bupivacaine (1.125 mL)
Study: 7714743
Drug: Formulation A
Normalized name: meningococcal vaccine of unknown formulation and unknown serogroups
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulation A (IPA/water/IPM; 11:7:1)
Study: 7714743
Drug: Formulation B
Normalized name: Hep B, unspecified formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulation B (ET/PG/IPM; 11:7:2)
Study: 7714743
Drug: Formulation C
Normalized name: Army Liposome Formulation component monophosphoryl lipid A
DrugBank: Monophosphoryl lipid A (DB19290)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulation C (IPM/capmul)
Study: 3066620
Drug: Mazindol 2
Normalized name: mazindol 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mazindol 2 mg
Study: 28682871
Drug: Enzalutamide (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enzalutamide (160 mg/d)
Study: 25627820
Drug: Goshajinkigan (GJG)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goshajinkigan (GJG) 7.5 mg three times daily
Study: 20709498
Drug: Intravenous nicorandil
Normalized name: nicorandil
DrugBank: Nicorandil (DB09220)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous nicorandil (0.2 mg/kg/5 min bolus followed by continuous infusion at 0.05, 0.10, or 0.20 mg/kg/h for 6h)
Study: 3150319
Drug: Intranasal buserelin
Normalized name: buserelin
DrugBank: Buserelin (DB06719)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal buserelin 400 micrograms three times daily for 6 months
Study: 3150319
Drug: Post-treatment (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-treatment (6 months after stopping buserelin)
Study: 3150319
Drug: During treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: During treatment with buserelin
Study: 30668196
Drug: Serum anti-Müllerian
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum anti-Müllerian hormone (AMH) levels measured using VIDAS®
Study: 30668196
Drug: AMH cutoff
Normalized name: Sodium Fluoride 0.007 mg in 35 mL ORAL SPRAY [AMHEALER]
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMH cutoff value of 42.1 pmol/L
Study: 19103558
Drug: Silymarin, 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silymarin, 2 x 166 mg/day for 3 months
Study: 17928596
Drug: Colonization with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colonization with S. pneumoniae, M. catarrhalis, H. influenzae, or a combination of these organisms
Study: 15385732
Drug: AMD3100 (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMD3100 (all doses)
Study: 11519973
Drug: Iron-fortified cow's
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron-fortified cow's milk (7.0 or 14.9 mg Fe l(‐1))
Study: 9683847
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy with cisplatin and adriamycin
Study: 9683847
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy with ifosfamide and etoposide added to cisplatin and adriamycin for poor histologic response
Study: 29352071
Drug: Aggressive diuresis
Normalized name: hydralazine hydrochloride / hydrochlorothiazide / reserpine Oral Tablet [Diuretic Ap-Es]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aggressive diuresis with high-dose loop diuretics (median 560 mg IV furosemide equivalents)
Study: 29352071
Drug: Aggressive diuresis
Normalized name: hydralazine hydrochloride / hydrochlorothiazide / reserpine Oral Tablet [Diuretic Ap-Es]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aggressive diuresis with high-dose loop diuretics
Study: 27510532
Drug: Oral Nutritional
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Nutritional Supplementation (ONS) during HD sessions for 12 weeks
Study: 27510532
Drug: Oral Nutritional
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Nutritional Supplementation (ONS) + Resistance Exercise (RE) during HD sessions for 12 weeks
Study: 24992949
Drug: Oral prednisone
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral prednisone for 8 days in tapering doses
Study: 24992949
Drug: Intratympanic prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intratympanic prednisolone at a dose of 62.5 mg/ml once a day for 3 consecutive days
Study: 22995032
Drug: Olive oil
Normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olive oil applied twice daily for 5 weeks
Study: 22995032
Drug: Sunflower seed
Normalized name: SUNFLOWER SEED
DrugBank: Sunflower seed (DB10907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunflower seed oil applied twice daily for 4 weeks
Study: 18232726
Drug: High-dose olanzapine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose olanzapine (mean dose, 34 mg/day)
Study: 18232726
Drug: Clozapine (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clozapine (mean dose, 564 mg/day)
Study: 11860612
Drug: Norepinephrine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norepinephrine (10 micrograms in 0.1 ml saline)
Study: 11860612
Drug: Saline (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline (0.1 ml)
Study: 1772457
Drug: Hemodialysate injection
Normalized name: ferric pyrophosphate
DrugBank: Ferric pyrophosphate citrate (DB13995)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hemodialysate injection (10 ml, 400 mg)
Study: 1772457
Drug: Hemodialysate infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hemodialysate infusion (500 ml, 4 g)
Study: 28822007
Drug: 3 ×
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 × 3 dose-dense cycles of intensified epirubicin, paclitaxel, and cyclophosphamide (ETC)